Daily Brief

What Did the Study Find?

GENIAL-CO randomised adults aged 50–74 undergoing post-polypectomy surveillance within an organised Italian colorectal-cancer screening programme to computer-aided detection or standard colonoscopy. Of 973 enrolled patients, 914 with adequate bowel preparation were analysed—455 with CADe and 459 controls.

CADe did not significantly improve the primary endpoint: adenoma detection was 66.6% versus 61.0% (P=0.160). Advanced-adenoma detection was similarly unchanged at 7.3% versus 6.3%, while sessile-serrated-lesion detection was 17.1% versus 14.2%. CADe did increase adenomas per colonoscopy from 1.32 to 1.80, but required longer withdrawal—16.35 versus 14.52 minutes, an additional 1.83 minutes per procedure. AI Medical Compendium

Why Does It Matter?

Finding additional small adenomas does not necessarily translate into more patients with clinically consequential neoplasia. In a high-performing surveillance programme with an already high baseline ADR, routine CADe added procedure time without significantly increasing advanced-lesion detection. Results may differ in lower-ADR settings, but they argue against assuming that AI automatically improves every colonoscopy population.

GastroAGI Takeaway

Judge colonoscopy AI by advanced-neoplasia and patient-level detection—not simply by how many additional diminutive adenomas the software highlights.

What Did the Study Find?

Investigators randomised 184 patients with cirrhosis, previous variceal bleeding, and a relatively small liver to covered TIPS created with a 7-mm or 8-mm stent. Median follow-up was 26.5 months; hepatitis B accounted for 56% of cirrhosis.

Overt hepatic encephalopathy developed in 20.7% with 7-mm versus 35.9% with 8-mm TIPS, an absolute reduction of 15.2 percentage points. Two-year cumulative incidence was 21.4% versus 37.2% (HR 0.52), while recurrent encephalopathy fell from 13.0% to 4.3%. Importantly, smaller diameter did not compromise efficacy: two-year rebleeding was 10.9% versus 9.8%, shunt dysfunction was 8.7% in both groups, and transplant-free survival was 91.3% versus 88.0%. pubmed.ncbi.nlm.nih.gov

Why Does It Matter?

TIPS sizing directly determines the balance between portal decompression and encephalopathy. These findings favour initial 7-mm deployment in carefully selected patients with smaller livers undergoing TIPS for secondary prevention. Generalizability is limited by the Chinese population, Fluency rather than Viatorr stents, and exclusion of portal-vein thrombosis and significant cardiopulmonary disease.

GastroAGI Takeaway

For variceal rebleeding prevention in cirrhosis with a small liver, 7-mm TIPS may provide the best haemodynamic compromise—substantially less encephalopathy with preserved shunt efficacy.

What Did the Guidance Recommend?

The AGA recommends moving beyond chronological age when deciding whether to continue pancreatic-cyst or hepatocellular-carcinoma surveillance. Patients with substantial comorbidity—an age-adjusted Charlson index of approximately 3–5 or higher—who would not undergo pancreatic surgery should generally be counselled against continued surveillance.

For a patient older than 65 years, surveillance cessation can be considered when a pancreatic cyst is ≤15 mm, has remained stable for five years and has no worrisome features or high-risk stigmata. For patients older than 75, the same discussion is appropriate for stable cysts <30 mm. Concerning growth remains at least 3 mm annually or 6 mm over two years.

HCC surveillance should continue in older adults with cirrhosis when potentially beneficial treatment remains realistic; age alone is not a reason to stop. Conversely, surveillance should generally cease when estimated life expectancy is under one to two years, including Child–Pugh C cirrhosis when transplantation is not an option. pubmed.ncbi.nlm.nih.gov

Why Does It Matter?

Surveillance is valuable only when detecting cancer can lead to meaningful treatment. The advice offers practical stopping thresholds, but it is expert guidance without formal systematic review or GRADE assessment.

GastroAGI Takeaway

Before ordering another surveillance scan, ask whether the patient could benefit from—and would accept—the intervention that a positive finding would trigger.

What Did the Study Find?

SIERRA prospectively evaluated first-line STRIDE—one dose of tremelimumab 300 mg plus durvalumab 1,500 mg, followed by durvalumab every four weeks—in 111 patients with unresectable HCC and poor-prognosis features. Participants had Child–Pugh B7/B8 disease (n=44), Child–Pugh A with ECOG performance status 2 (n=47), or chronic main-trunk portal-vein thrombosis/Vp4 (n=20).

Grade 3–4 adverse events considered possibly treatment-related within six months occurred in 19.8% overall: 18.2%, 19.1% and 25.0% across the three cohorts, respectively. Investigator-assessed objective response was 14.4% overall, but varied substantially—6.8% in Child–Pugh B7/B8, 21.3% with ECOG 2 and 15.0% with Vp4. There was no sorafenib, lenvatinib or immunotherapy comparator. pubmed.ncbi.nlm.nih.gov

Why Does It Matter?

Up to two-thirds of real-world advanced-HCC patients may have characteristics underrepresented in phase 3 trials. SIERRA provides valuable prospective safety data, but the modest Child–Pugh B response and single-arm design mean that preserved-liver-function trial results cannot simply be extrapolated to every decompensated patient.

GastroAGI Takeaway

STRIDE is feasible in selected poor-prognosis HCC, but Child–Pugh B treatment requires individualized assessment and should not be regarded as fully validated by SIERRA alone.